Mego Marianela, Huaman José Wálter, Videla Sebastian, Jansana Marta, Tinoco Karen, Saperas Esteban
Servicio de Gastroenterología, Hospital Universitari General de Catalunya, Grupo QuirónSalud, Sant Cugat del Vallès, Barcelona, España.
Servicio de Gastroenterología, Hospital Universitari General de Catalunya, Grupo QuirónSalud, Sant Cugat del Vallès, Barcelona, España; Escuela de Medicina, Universitat Internacional de Catalunya, Barcelona, España.
Gastroenterol Hepatol. 2023 Dec;46(10):774-783. doi: 10.1016/j.gastrohep.2023.01.012. Epub 2023 Jan 31.
Fiber is the initial treatment in chronic functional constipation. However, its role in the group of patients with defecatory dyssynergy is not well established. The objective of the study is to evaluate the efficacy and safety of a high fiber diet in patients with defecatory dyssynergy in the treatment with anorectal biofeedback.
An exploratory, randomized (1:1), double-blind, controlled «add-on» clinical trial was carried out in a reference center in Spain in patients with functional constipation and defecatory dyssynergy according to the ROMEIV criteria.
treatment with biofeedback and low-fiber diet (15-20g/day). Experimental group: treatment with biofeedback and high fiber diet (25-30g/day). Analyzed: responder (primary endpoint), patient whose defecatory dyssynergy had been corrected (>20% reduction in anal pressure during the defecation maneuver and normal balloon expulsion test); anorectal parameters (anal relaxation, reduced straining); safety (abdominal symptoms: flatulence, pain, borborygmus, bloating).
A total of 44 patients were randomized: 22 per group. The percentage of responders was 75% (15/20; 95%CI: 53 89%) control group and 70% (14/20; 95%CI: 48-85%) experimental group, P=.225. Differences in favor of the control group were only observed in abdominal symptoms: flatulence (P=.028), abdominal distension (P=.041) and digestive comfort (P=.043).
In patients with defecatory dyssynergy, a high-fiber diet not only does not improve the efficacy of anorectal biofeedback but is associated with a loss of improvement in abdominal symptoms.
纤维是慢性功能性便秘的初始治疗方法。然而,其在排便协同失调患者群体中的作用尚未明确。本研究的目的是评估高纤维饮食在排便协同失调患者接受肛门直肠生物反馈治疗中的疗效和安全性。
在西班牙的一个参考中心,针对符合罗马IV标准的功能性便秘和排便协同失调患者,开展了一项探索性、随机(1:1)、双盲、对照“附加”临床试验。
采用生物反馈和低纤维饮食(15 - 20克/天)治疗。实验组:采用生物反馈和高纤维饮食(25 - 30克/天)治疗。分析指标:反应者(主要终点),即排便协同失调得到纠正的患者(排便动作时肛门压力降低>20%且球囊排出试验正常);肛门直肠参数(肛门松弛、用力减少);安全性(腹部症状:肠胃胀气、疼痛、肠鸣、腹胀)。
共44例患者被随机分组:每组22例。对照组反应者百分比为75%(15/20;95%置信区间:53 - 89%),实验组为70%(14/20;95%置信区间:48 - 85%),P = 0.225。仅在腹部症状方面观察到对照组有优势:肠胃胀气(P = 0.028)、腹胀(P = 0.041)和消化舒适度(P = 0.043)。
在排便协同失调患者中,高纤维饮食不仅不能提高肛门直肠生物反馈的疗效,还会导致腹部症状改善情况变差。